Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
CLLS
Cellectis S.A. American
$1.47
Chart
$1.38 (+6.52%)
$1.25 (+17.60%)
$1.56 (-5.77%)
$2.25 (-34.67%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
CLLS
Cellectis S.A. American
Current Price
$1.47
Login to view Cellectis S.A. American (CLLS) recommendation from the last 90 days from financial news and social media.
Chart
$1.38 (+6.52%)
$1.25 (+17.60%)
$1.56 (-5.77%)
$2.25 (-34.67%)
CLLS Latest Headlines
Cellectis Non-GAAP EPS of -$0.17 revenue of $12M misses by $1.83M.
Mon May 12, 2025
Cellectis Reports Financial Results for the First Quarter 2025. Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&.D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies one allogeneic CAR T for solid tumors and one in vivo gene the
Mon May 12, 2025
Cellectis Reports Financial Results for the First Quarter 2025. Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&.D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies one allogeneic CAR T for solid tumors and one in vivo gene the
Mon May 12, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CLLS Stock trends
CLLS Stock performance
CLLS Stock analysis
CLLS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
